Upgrade to SI Premium - Free Trial

Form SCHEDULE 13G/A TENAX THERAPEUTICS, INC. Filed by: Lind Global Fund II LP

May 15, 2026 4:20 PM





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: The reporting person's ownership consists of 202,480 warrants to purchase shares of common stock (the "Warrants"). Such Warrants may not be exercised if, following such exercise, the reporting person's beneficial ownership would exceed 9.9%.


SCHEDULE 13G




Comment for Type of Reporting Person: The reporting person's ownership consists of 202,480 Warrants. Such Warrants may not be exercised if, following such exercise, the reporting person's beneficial ownership would exceed 9.9%


SCHEDULE 13G




Comment for Type of Reporting Person: The reporting person's ownership consists of 202,480 Warrants. Such Warrants may not be exercised if, following such exercise, the reporting person's beneficial ownership would exceed 9.9%.


SCHEDULE 13G



Lind Global Fund II LP
Signature:By: Lind Global Partners II LLC, its General Partner, By: /s/ Jeff Easton
Name/Title:Jeff Easton, Managing Member
Date:05/15/2026
Lind Global Partners II LLC
Signature:/s/ Jeff Easton
Name/Title:Jeff Easton, Managing Member
Date:05/15/2026
EASTON JEFF
Signature:/s/ Jeff Easton
Name/Title:Jeff Easton
Date:05/15/2026

Categories

SEC Filings